Search Results 581-590 of 18360 for alopecia

1. A Study To Investigate The Safety And Tolerability Of Ziftomenib In Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, Or 7+3+Quizartinib In Patients With AML - Mayo Clinic

   ... alopecia * Known clinically active human immunodeficiency virus, active hepatitis B or active hepatitis C infection * For newly diagnosed cohorts: received ...

2. Publications - Tufia C. Haddad, M.D. - Mayo Clinic

   ... alopecia in breast cancer. Support Care Cancer. 2024 Jun 6; 32 (7):412 Epub 2024 June 06. View PubMed; Haemmerle R, Paludo J, Haddad TC, Pritchett JC. The ...

3. A Study of Response, Survival, Safety, and Tolerability of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer - Mayo Clinic

   ... alopecia, and irreversible late sequelae of radiation therapy, must have resolved to Grade 0 or 1 per Common Terminology Criteria for Adverse Events (CTCAE ...

4. A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma - Mayo Clinic

   0, except for alopecia. Patients with chronic but stable Grade 2 toxicities may be allowed to enroll after an agreement between the Investigator and Sponsor ...

5. A Study to Evaluate T-DM1 With or Without Abemaciclib in Women and Men with HER2-positive Advanced or Metastatic Breast Cancer - Mayo Clinic

   NOTE: All residual toxicities (except alopecia) should be at baseline or grade 1 (including peripheral neuropathy). NOTE: If indicated, patients can ...

6. Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer - Mayo Clinic

   ... alopecia and peripheral neuropathy. Have adequate organ function, including: Hematologic: absolute neutrophil count ≥1.5 × 10⁹/Liter (L), platelets ≥100 ...

7. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

   Patients with any grade of alopecia are allowed to enter the study. Patients must have adequate organ function; ECOG performance status (PS) of 0 or 1 ...

8. A Study to Evaluate Pemetrexed and Pembrolizumab to Treat Recurrent and/or Metastatic Salivary Gland Malignancies - Mayo Clinic

   Participation eligibility · Exceptions: Neuropathy, fatigue, and/or alopecia may be Grade 1. · Known active central nervous system (CNS) metastases. NOTE: ...

9. A Study to Evaluate AVID200 in Myelofibrosis Patients - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia. Women of child bearing potential (WCBP), defined ...

10. A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression - Mayo Clinic

    Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE v.3.0 Grade ≤ 1 and to baseline laboratory values as defined in the ...